Astellas reports FDA approval of anti-rejection drug – NephrologyNews.com
|
Astellas reports FDA approval of anti-rejection drug
NephrologyNews.com The drug is used with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction. “Each transplant recipient is different and requires a personalized treatment approach,” said Sef Kurstjens, MD, PhD., chief medical officer … |
